AI Article Synopsis
- The study investigated genetic mutations in 55 surgical tumors from stage IB-IIB cervical cancer patients to understand their role in tumor progression and treatment outcomes.
- A total of 52 mutations were found in 63.6% of the patients, with PIK3CA being the most common mutation, and the presence of mutations correlated with pelvic lymph node metastasis and worse overall survival.
- The findings suggest that analyzing multiple genetic mutations can serve as a predictive biomarker for metastasis and prognosis in early-stage cervical cancer.
Article Abstract
It is well known that tumour initiation and progression are primarily an accumulation of genetic mutations. The mutation status of a tumour may predict prognosis and enable better selection of targeted therapies. In the current study, we analysed a total of 55 surgical tumours from stage IB-IIB cervical cancer (CC) patients who had undergone radical hysterectomy including pelvic lymphadenectomy, using a cancer panel covering 50 highly mutated tumorigenesis-related genes. In 35 patients (63.6%), a total 52 mutations were detected (58.3% in squamous cell carcinoma, 73.7% in adenocarcinoma), mostly in PIK3CA (34.5%) and KRAS and TP53 (9.1%). Being mutation-positive was significantly correlated with pelvic lymph node (PLN) metastasis (P = 0.035) and tended to have a worse overall survival (P = 0.076). In particular, in the patients with squamous cell carcinoma, there was a significant association between being mutation-positive and relapse-free survival (P = 0.041). The patients with PLN metastasis had a significantly worse overall survival than those without (P = 0.006). These results indicate that somatic mutation status is a predictive biomarker for PLN metastasis in early-stage CC, and is consequently related to poor prognosis. Therefore, comprehensive genetic mutations, rather than a single genetic mutation, should be examined widely in order to identify novel genetic indicators with clinical usefulness.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599240 | PMC |
| http://dx.doi.org/10.1038/s41598-020-72518-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer.
Prostate Cancer Prostatic Dis
January 2025
South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia.
Article Synopsis
- The study analyzes how clinical risk stratification can be used to assess the advantages of long-term androgen deprivation therapy (ltADT) compared to short-term therapy (stADT) in high-risk localized prostate cancer patients.
- Results indicate that patients with very-high risk features have greater improvements in survival outcomes when treated with ltADT, although the variation in treatment effects across different risk groups is not statistically significant.
- The findings suggest the need for further clinical trials to refine risk stratification methods and better identify which high-risk localized prostate cancer patients could benefit more from longer therapy.
Prognostic Implications of the Number of Lymph Node Metastases in Oral Tongue Squamous Cell Carcinoma: A Population Study of the SEER Database and an Institutional Registry.
Cancer Med
December 2024
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Background: To investigate the impact of the number of positive lymph nodes (PLNs) on long-term survival and pathological nodal stage in patients with oral tongue squamous cell carcinoma (OTSCC).
Materials And Methods: Newly diagnosed and nonmetastatic adult patients with OTSCC who underwent curative resection were identified between January 2010 and December 2020. External validation was performed via the SEER registry.
Risk Factor Analysis and Prediction of Para-Aortic Lymph Node Metastases in Locally Advanced Cervical Cancer.
Cancer Med
December 2024
Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Background And Purpose: The indications of prophylactic extended-field radiotherapy (EFRT) remain uncertain. This study aims to identify the risk factors for para-aortic lymph node (PALN) metastases in locally advanced cervical cancer (LACC) and determine which part of patients may benefit from prophylactic EFRT.
Materials And Methods: Between January 2015 and July 2023, a single-center retrospective analysis was performed on patients with stages IB3 and IIA2-IVA cervical cancer.
Nanoparticulate drug combination inhibits DNA damage repair and PD-L1 expression in BRCA-mutant and wild type triple-negative breast cancer.
J Control Release
January 2025
Advanced Pharmaceutics and Drug Delivery Laboratory, Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto M5S 3M2, Ontario, Canada. Electronic address:
Article Synopsis
- Metastatic breast cancer has a high mortality rate and is hard to treat, especially in triple-negative breast cancer (TNBC) due to factors like DNA repair and immunosuppression.
- PARP inhibitors like olaparib can help, but problems like drug resistance and increased PD-L1 can limit their effectiveness.
- The study tested a new treatment using specialized polymer-lipid nanoparticles carrying doxorubicin to target TNBC, showing better results in reducing tumor growth and metastasis compared to olaparib.
Better Oncological Outcomes After Prostate-specific Membrane Antigen Positron Emission Tomography-guided Salvage Radiotherapy Following Prostatectomy.
Eur Urol Focus
November 2024
Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address:
Background And Objective: Up to 50% of patients with prostate cancer experience prostate-specific antigen (PSA) relapse following primary radical prostatectomy (RP). Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is increasingly being used for staging after RP owing to its high detection rate. Our aim was to compare outcomes for patients who received salvage radiotherapy (sRT) with versus without PSMA PET guidance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!